MDM2 and neoplasm: Together, the above results demonstrated that all three pair-wise combinations of MDM2, MAPK, and PI3K pathway inhibitors could elicit broad and robust synergy across a wide array of tumor cell lines, and they raised the possibility that triple combinations of agents targeting these key oncogenic pathways might enhance therapeutic index (the ratio between the therapeutic dose and the toxic dose) and evoke durable clinical responses.